Alteco endotoxin hemoadsorption in Gram-negative septic shock patients

Indian Journal of Critical Care Medicine

Volumn 18, Issue 12, 2014, Pages 783-788

  Shum, Hoi Ping ^a   Leung, Yuk Wah ^a   Lam, Sin Man ^a   Chan, King Chung ^a   Yan, Wing Wa ^a  

^a PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

Author keywords

Endotoxins; hemoadsorption; outcome; septic shock

Indexed keywords

ANTIBIOTIC AGENT; ENDOTOXIN; HYDROCORTISONE; LOW MOLECULAR WEIGHT HEPARIN; NORADRENALIN; TINZAPARIN;

ADULT; AGED; ANALYTICAL EQUIPMENT; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; DOSE RESPONSE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HEMADSORPTION; HEMOADSORBER; HUMAN; HYPOTENSION; LENGTH OF STAY; MORTALITY; OPEN STUDY; PROBABILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 84919666773     PISSN: 09725229     EISSN: 1998359X     Source Type: Journal    
DOI: 10.4103/0972-5229.146305     Document Type: Article

References (32)

1. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-8.
2. Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 2001;7:167-202.
3. Beutler B, Poltorak A. Positional cloning of Lps, and the general role of toll-like receptors in the innate immune response. Eur Cytokine Netw 2000;11:143-52.
4. Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: Results of the MEDIC study. J Infect Dis 2004;190:527-34.
5. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991;266:1097-102.
6. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995;23:994-1006.
7. Suzuki H, Shoji H. Application of polymyxin B convalently immobilized fiber in patients with septic shock. Contrib Nephrol 2010;166:150-7.
8. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: A systematic review. Crit Care 2007;11:R47.
9. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: The EUPHAS randomized controlled trial. JAMA 2009;301:2445-52.
10. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
11. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34:17-60.
12. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-12.
13. Ala-Kokko TI, Laurila J, Koskenkari J. A new endotoxin adsorber in septic shock: Observational case series. Blood Purif 2011;32:303-9.
14. Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute Physiology and Chronic Health Evaluation (APACHE) IV: Hospital mortality assessment for today's critically ill patients. Crit Care Med 2006;34:1297-310.
15. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
16. Zuppa AF, Nadkarni V, Davis L, Adamson PC, Helfaer MA, Elliott MR, et al. The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. Crit Care Med 2004;32:2318-22.
17. Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002;30:100-6.
18. Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E, et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: A randomized controlled trial. Crit Care Med 2009;37:803-10.
19. Rimmelé T, Kellum JA. High-volume hemofiltration in the intensive care unit: A blood purification therapy. Anesthesiology 2012;116:1377-87.
20. Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM, Grand H, Canivet JL, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): A multicentre randomized controlled trial. Intensive Care Med 2013;39:1535-46.
21. Atan R, Crosbie D, Bellomo R. Techniques of extracorporeal cytokine removal: A systematic review of the literature. Blood Purif 2012;33:88-100.
22. Formica M, Inguaggiato P, Bainotti S, Wratten ML. Coupled plasma filtration adsorption. Contrib Nephrol 2007;156:405-10.
23. Hu D, Sun S, Zhu B, Mei Z, Wang L, Zhu S, et al. Effects of coupled plasma filtration adsorption on septic patients with multiple organ dysfunction syndrome. Ren Fail 2012;34:834-9.
24. Mitaka C, Tomita M. Polymyxin B-immobilized fiber column hemoperfusion therapy for septic shock. Shock 2011;36:332-8.
25. Ullrich H, Jakob W, Fröhlich D, Rothe G, Prasser C, Drobnik W, et al. A new endotoxin adsorber: First clinical application. Ther Apher 2001;5:326-34.
26. Staubach KH, Boehme M, Zimmermann M, Otto V. A new endotoxin adsorption device in Gram-negative sepsis: Use of immobilized albumin with the MATISSE adsorber. Transfus Apher Sci 2003;29:93-8.
27. Reinhart K, Meier-Hellmann A, Beale R, Forst H, Boehm D, Willatts S, et al. Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected Gram-negative sepsis. Crit Care Med 2004;32:1662-8.
28. Kulabukhov VV. Use of an endotoxin adsorber in the treatment of severe abdominal sepsis. Acta Anaesthesiol Scand 2008;52:1024-5.
29. Yaroustovsky M, Abramyan M, Popok Z, Nazarova E, Stupchenko O, Popov D, et al. Preliminary report regarding the use of selective sorbents in complex cardiac surgery patients with extensive sepsis and prolonged intensive care stay. Blood Purif 2009;28:227-33.
30. Maury E, Blanchard HS, Chauvin P, Guglielminotti J, Alzieu M, Guidet B, et al. Circulating endotoxin and antiendotoxin antibodies during severe sepsis and septic shock. J Crit Care 2003;18:115-20.
31. Dholakia S, Inwald D, Betts H, Nadel S. Endotoxemia in pediatric critical illness-A pilot study. Crit Care 2011;15:R141.
32. Monti G, Bottiroli M, Pizzilli G, Minnini M, Terzi V, Vecchi I, et al. Endotoxin activity level and septic shock: A possible role for specific anti-endotoxin therapy? Contrib Nephrol 2010;167:102-10.